SAR3419 in Acute Lymphoblastic Leukemia

Overview

Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics

The duration of the study for an individual patient will include: * The screening period = up to 4 weeks prior to the first administration of SAR3419. * The treatment period: * Induction period = 4 to 8 weeks * Maintenance = up to a total maintenance treatment of 6 months * A safety follow-up period of 42 days after the last dose. * Any patient who discontinues the study treatment without disease progression will be followed every 2 months until disease progression, initiation of a new anti-cancer therapy, death or end-of-study date, whatever comes first.

Conditions

Interventions

Eligibility

Locations (11)

Outcomes